Browsing St. Luke's Radiation Oncology Network, Dublin by Subjects
Now showing items 1-1 of 1
-
ADAM-17: a novel therapeutic target for triple negative breast cancer.Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.